Brain-derived neurotrophic factor (BDNF)

Overview

Brain derived neurotrophic factor (BDNF) is a secreted neurotrophin encoded by the BDNF gene and is widely recognized as a key regulator of neuronal survival, differentiation, synaptic plasticity, and activity-dependent remodeling in the central nervous system. It signals primarily through the tyrosine kinase receptor B (TrkB) pathway, influencing downstream programs involved in learning, memory, neurite outgrowth, and resilience to injury. Because of these functions, BDNF is frequently discussed in the context of cognitive function, neuroinflammation, oxidative stress, and neurodegenerative disease.

In biomedical research, BDNF is often treated as both a mechanistic marker and a therapeutic target. Altered BDNF expression or signaling has been associated with conditions such as Alzheimer’s pathology, related dementia, diabetes-associated brain dysfunction, mild cognitive impairment, Huntington’s disease-like phenotypes, amyotrophic lateral sclerosis, ischemic brain injury, and traumatic brain injury. Experimental studies commonly examine whether interventions restore BDNF levels, enhance BDNF/TrkB signaling, or rebalance proBDNF/mBDNF processing as part of broader neuroprotective effects.

Recent Publications Summary (latest 30 papers)

Recent studies continued to position BDNF as a key mediator and therapeutic target in neurodegeneration, stroke, and neuroinflammation. In a subacute stroke model, focused magnetic stimulation was used to enhance BDNF delivery across the blood-brain barrier, and the combination significantly increased BDNF accumulation in the ipsilesional brain and produced a robust reduction in infarct volume compared with BDNF alone 42140057May. In ischemic brain injury, dexmedetomidine was also investigated for cerebral protection through activation of the BDNF/TrkB pathway 42015734Apr, while Fujian Tablets were reported to improve motor recovery after MCAO by regulating BDNF shearing enzyme-mediated proBDNF/mBDNF balance 41548621Jan.

Several publications linked BDNF signaling to cognitive and synaptic outcomes in experimental neurodegenerative models. In an Alzheimer’s disease rat model, dysregulation of Drp1 and Mfn2 was associated with reduced PSD-95, synaptophysin, and BDNF expression in the hippocampus and cortex 41932483Apr. Another study found that hydrophobic interior-modified ferritin enabled more efficient lycopene delivery and improved aging-related cognitive impairment in D-galactose-treated mice, with effects mediated through BDNF/TrkB 42009517Apr. In a scopolamine-induced amnesia model, Schinus molle essential oil was also reported to improve cognition and alter hippocampal BDNF/GFAP levels 41633493Feb.

BDNF was further examined in inflammatory and neuropsychiatric contexts. In a repetitive mild traumatic brain injury mouse model, intranasal mRNA-loaded lipid nanoparticle co-delivering BDNF and IL-10 reduced neuroinflammation, inhibited neuronal death, and improved cognition 42157518May. In chronic coronary syndrome, a 12-week exercise intervention assessed changes in BDNF alongside movement behaviors, cardiorespiratory fitness, and cardiometabolic risk, with longitudinal associations analyzed over follow-up 42323275Jun. In monozygotic twins discordant for pain-related temporomandibular disorder, lower peripheral BDNF levels were associated with greater symptom burden and co-occurred with inflammatory and oxidative alterations 42132960May.

Additional studies highlighted BDNF-related genetic and disease-modifying effects. In amyotrophic lateral sclerosis, BDNF insufficiency was linked to reduced patient survival, and BDNF haploinsufficiency in mice accelerated motor dysfunction and motor neuron death, whereas TrkB activation rescued these phenotypes 42013845Apr. A study of the BDNF Val66Met polymorphism found increased serotonin-transporter binding in the medial prefrontal cortex in met-carriers but no clear effect on eating behavior 41802488Mar. Reviews also noted aberrant methylation at the BDNF locus among epigenetic signatures implicated in chronic pain-associated neuropsychiatric comorbidities 41554641Jan.

What Changes, What Holds

1. BDNF is being pushed from a general neurotrophic factor toward a delivery-limited stroke therapy
REINFORCES Focused magnetic stimulation appears to improve how much exogenous BDNF reaches injured brain tissue and thereby strengthens the already established idea that BDNF can be neuroprotective in ischemic injury 42140057May. The important change is practical rather than conceptual: the limiting step may be access across the blood-brain barrier, not lack of biological activity. dexmedetomidine and proBDNF/mBDNF balancing studies in the same paragraph further support the stroke/neuroprotection framing 42015734Apr41548621Jan.

2. BDNF remains a downstream marker of synaptic and cognitive preservation in neurodegeneration
REINFORCES These studies do not displace the baseline account that BDNF tracks neuronal resilience and learning-related plasticity; instead, they add more experimental settings in which reduced BDNF accompanies impaired cognition or synaptic integrity 41932483Apr42009517Apr. The ferritin-lycopene result is especially consistent with BDNF/TrkB as a mediator of cognitive benefit, while the Alzheimer’s model reinforces BDNF loss as part of broader synaptic pathology rather than a separate phenomenon.

3. BDNF is increasingly treated as a modifiable node in inflammation-linked brain injury and systemic disease
REINFORCES Intranasal co-delivery of BDNF with IL-10 in traumatic brain injury strengthens the established neuroprotective role of BDNF by placing it within an anti-inflammatory repair strategy 42157518May. The exercise and temporomandibular disorder findings extend BDNF into longitudinal cardiometabolic and pain-associated inflammatory contexts, but those are additions to the baseline rather than reversals of it 42323275Jun42132960May. Together they suggest BDNF is a broad response marker, not just a CNS trophic factor.

4. BDNF insufficiency now looks like a disease-modifying liability in ALS, not merely an associated biomarker
REINFORCES The new ALS work sharpens the baseline by linking low BDNF to survival and motor decline, and by showing that restoring TrkB signaling can rescue the phenotype 42013845Apr. That fits the established view of BDNF as a therapeutic target in neurodegeneration, but it raises the stakes: in this setting, BDNF appears to be functionally limiting rather than just correlated with disease severity. The Val66Met and methylation findings add genetic and epigenetic context without changing that core interpretation 41802488Mar41554641Jan.

Overview update candidates: BDNF delivery across the blood-brain barrier may be a practical determinant of stroke efficacy; BDNF insufficiency may be disease-modifying in ALS; BDNF continues to serve as a broad marker and mediator of synaptic/cognitive preservation across neurodegenerative and inflammatory settings.